Learn to differentiate between “label” and “labeling” and “false and “misleading”. Gain insight on FDA’s social media guidance, use of off-label information, and considerations for other government and state entities. Understand the role of a corporate compliance program in managing the risks of marketing a drug.
Alan G. Minsk, Partner, Arnall Golden Gregory LLP
This session was recorded as part of FDLI’s Introduction to Drug Law and Regulation Course in April 2022.